GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare pharmacokinetics, safety and tolerability of different formulations (tablets and capsules) and dosage (50 and 200mg) of GNS561 after single oral administration in first part and to evaluate the food effect on pharmacokinetics in second part.

开始日期2022-05-02

申办/合作机构

Genoscience Pharma

NCT02998593 / Unknown status临床3期IIT

Effect of Red and White Bahman on Semen Parameters,Testosteron ,LH, FSH and Defragmentation of DNA . A Double Blind Randomised Clinical Trial (Phase 3)

This study is a prospective double blind randomized controlled trial to investigate the effect of red and white bahman on semen parameters, sexual hormones and DNA defragmentation in idiopathic oligospermic men .Include patients will take the medicine and placebo in different two case and control groups for 3 month and semen parameters and other variants at the start and end of study.

开始日期2016-07-01

申办/合作机构

Royan Institute

NCT02642250 / Completed临床2/3期IIT

Chemical, Biological and Comparative Clinical Evaluation of Entoban to Determine Safety and Efficacy for the Treatment of Chronic Diarrhea

Revival of significance and the emergent market of herbal medicinal products necessitate strong commitment by the stakeholders to safeguard the end users. The variability in the concentrations of constituents of plant material, coupled with the variety of extraction techniques and processing steps used by different manufacturers, results in distinct inconsistency in the quality of herbal products. The present study will be directed to a polyherbal formulation Entoban which integrates an outstanding blend of herbs that have been used for decades to eradicate microorganisms and worms from gastrointestinal tract. It is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora. The current study would target the chemical assessment, pharmacological and comparative clinical evaluation of Entoban to assure its safety and efficacy.

开始日期2015-01-01

申办/合作机构

Shifa Ul Mulk Memorial Hospital

100 项与 Entoban 相关的临床结果

登录后查看更多信息

100 项与 Entoban 相关的转化医学

登录后查看更多信息

100 项与 Entoban 相关的专利（医药）

登录后查看更多信息

项与 Entoban 相关的文献（医药）

2016-11-01·Pakistan journal of pharmaceutical sciences

Efficacy and safety of Entoban for the treatment of chronic diarrhea.

Article

作者: Usmanghani, Khan ; Shakeel, Sadia ; Asif, Hafiz Muhammad

The current randomized clinical trial was conducted to assess the safety and effectiveness of Entoban for treating patients of chronic diarrhea. The study enrolled 150 patients fulfilling the inclusion criteria, among them 95 were males and 55 were females. Written informed consent was obtained from all study participants. Metronidazole tablets (400 mg) were used in a control group for 7-10 days. The test group received Entoban capsule 400mg every 8 hours for five days. Primary outcome of the study was daily bowel frequency evaluation; the secondary outcome was evaluation of clinical symptoms including abdominal pain, distention, stool consistency and sensation of incomplete evacuation. The study is registered at (https://register.clinicaltrials.gov) having registration number NCT02642250. In an intention-to-treat (ITT) analysis, it has been observed that 39(84.78%) in test group and 37(78.72%) in control group showed complete improvement. Participants in the test group exhibited a marked reduction in symptoms; the symptom score was decreased from 3 (maximum) to 1 (minimum) or 0 (absent) in most of participants. Major difference was observed regarding side effects reported between two treatment groups (p value <0.0001). Entoban possesses considerable therapeutic efficacy for the treatment of chronic diarrhea analogous with the conventional Metronidazole therapy.

项与 Entoban 相关的新闻（医药）

2023-07-05

·药通社

进口成品制剂推荐：利扎曲普坦片、卡巴拉汀胶囊、齐拉西酮胶囊

2023年8月3日-4日第五届中国国际生物 & 化学制药博览会展位号：E-D05▼公司简介天津乾启医药科技有限公司创立于2009年，是一家专注于原料药及制剂进口和技术服务的科技型企业。乾启致力于寻找、引进全球领先的原料药及制剂产品和技术，服务于中国的医药企业。目前已和多家全球知名医药企业建立长期战略合作关系，全权负责其相关产品在中国市场的专业推广。——乾启医药产品介绍利扎曲普坦片英文名称：Rizatriptan tablets规格：5mg,10mg上市国：美国产地：印度利扎曲普坦片是临床用来治疗偏头痛的一种特异性治疗药物，《中国偏头痛诊断治疗指南2011》指出，苯甲酸利扎曲普坦片的头痛消失与疗效维持在所有曲坦类药物中最显著，头痛复发率最低。利扎曲普坦是第二代曲坦类药物；在《国家医保目录》中属于“神经系统用药”中的“抗偏头痛药物” ；在药理作用层面上属于5-HT1B/1D受体激动剂；在《中国偏头痛诊断治疗指南2011》中属于偏头痛急性发作期特异性治疗药物；在《美国偏头痛循证指南2000》中属于偏头痛发作期治疗的A级推荐药物。利扎曲普坦片可针对成人有或无先兆的偏头痛发作的急性治疗；FDA（美国食品药品监督管理局）已批准用于儿童、青少年偏头痛（6-17岁）急性治疗。包括有先兆偏头痛、无先兆偏头痛、经期偏头痛、儿童偏头痛、前庭性偏头痛等。卡巴拉汀胶囊调研英文名称：Rivastigmine capsules规格：1.5mg,3.0mg,4.5mg,6.0mg上市国：美国产地：印度卡巴拉汀又名利斯的明，是美国FDA批准的用于治疗老年性痴呆的一种假性不可逆性乙酰胆碱酯酶抑制剂，用于治疗轻、中度阿尔茨海默型痴呆，能够明显延缓痴呆进程，改善患者的临床症状、认知功能、精神症状，具有良好依从性。流行病学数据显示，中国60岁以上痴呆患病率为5.3％，其中阿尔茨海默型痴呆占痴呆人数的50~70％，近500~650万患者，成为严重的社会和家庭疾病负担。阿尔茨海默症的病理改变主要累及从前脑基底部发出至大脑皮质和海马的胆碱神经通路。重酒石酸卡巴拉汀作为一种氨基甲酸类选择性乙酰胆碱酯酶抑制剂，通过延缓功能完整的胆碱能神经元所释放的乙酰胆碱的降解而促进胆碱能神经传导，其有效性得到临床广泛验证，在国内外指南中均作为一线治疗药物进行推荐。2019年中国阿尔茨海默病市场规模接近10亿元。齐拉西酮胶囊英文名称：Ziprasidone Capsules规格：150mg,200mg,300mg,400mg上市国：美国产地：印度齐拉西酮——疗效优越的新型非典型抗精神病药，是继氯氮平(clozapine)、利培酮(risperidone)、奥氮平(olanzapine)和喹硫平(quetiapine)之后，全球上市的第5个非典型抗精神病药物(《世界临床药物》)。随着患者基数不断增加，越来越多的精神分裂症患者得到规范诊治，我国精神分裂症药物行业市场规模将快速增长。根据数据显示，我国精神分裂症药物行业市场规模从2016年的64.1亿元增至2020年的72.7亿元，预计到2025年将达到100亿元。联系我们电话：15710295101、15710295102网址：www.apocalypse-pharma.com地址：天津经济技术开发区洞庭路220号，天津国际生物医药联合研究院会议楼C320扫描二维码立即参会报名▼8月03-04日第五届中国国际生物&化学制药博览会限时免费报名中，点击图片了解会议详情↓↓

临床结果申请上市

100 项与 Entoban 相关的药物交易

登录后查看更多信息